Dublin biotech firm has recommended flattering results in clinical testing of a vaccine designed to fight Alzheimer's disease.

According to Bloomberg, United Neuroscience Inc. talks, actually that in the recent testing of the vaccine, called UB-311, 96 % of patients responded to the healing, without serious side effects.

"We are doing more than any other than a placebo on all these things," says key Executive Director may Mei Hu. "We can not yet create almost no statements, but we show in all the right instructions.”

Scientists talk, in fact, that there are a number of suspected grounds for the formation of Alzheimer's disease: the accumulation of amyloids, protiens, actually that stick together in the brain; Tau, a different group of protiens with similar effects, and inflammation in General.

Scientists have not been able to destroy the "blood brain barrier" the body to heal disease. The blood-brain obstacle defends opposite circulating toxins or pathogens that have managed to cause brain infections, but still shields outside medications that would shoot dementia-causing proteins.

The United vaccine initiates the patients ' personal immune system to attack the build-up of amyloid, slowing the capacity of the protiens to clump, and by ability directs some damage and resumes brain function.

Clinical analysis United consisted of 42 patients who suffered from mild cognitive impairment or early onset of Alzheimer's disease. The group was divided into 3 groups; 1 control group received a placebo, and 2 other groups received 3 vaccinations and boosters any three to six months in the direction of one and a half years.

According to Bloomberg, based on the positive results, the firm was encouraged to continue to go forward in the development of the vaccine.